Anti-GPC3 chimeric antigen receptor T cell therapy - Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine

Drug Profile

Anti-GPC3 chimeric antigen receptor T cell therapy - Hunan Yongren Medical Innovation/Guangdong Zhaotai InVivo Biomedicine

Alternative Names: Anti-GPC3 CAR-T cells; Anti-GPC3 chimeric antigen receptor T cell therapy - Guangdong Zhaotai InVivo Biomedicine/Hunan Yongren Medical Innovation; CAR-GPC3-T-cells; Glypican-3- chimeric-antigen-receptor-T-cell-therapy - Hunan Yongren Medical Innovation; GPC3-CAR-T cell therapy - Hunan Yongren Medical Innovation; GPC3-T2-CAR-T cell therapy

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Guangdong Zhaotai InVivo Biomedicine; Hunan Yongren Medical Innovation
  • Developer Hunan Yongren Medical Innovation
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Glypican 3 modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma; Lung cancer

Most Recent Events

  • 01 Jul 2017 Phase-I clinical trials in Lung cancer (Late-stage disease) in China (Parenteral) (NCT03198546)
  • 21 Jun 2017 Hunan Zhaotai Yongren Medical Innovation and Guangdong Zhaotai InVivo Biomedicine in collaboration with Guangzhou Medical University plan a phase I trial for Hepatocellular carcinoma and Lung cancer (Late-stage disease) in China (NCT03198546)
  • 21 Jun 2017 Preclinical trials in Hepatocellular carcinoma in China prior to June 2017 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top